{"id":"NCT03439657","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-12","primaryCompletion":"2019-05-06","completion":"2020-03-03","firstPosted":"2018-02-20","resultsPosted":"2021-03-18","lastUpdate":"2022-01-11"},"enrollment":913,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"HZ/su vaccine GSK1437173A","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar13","otherNames":["PCV13"]}],"arms":[{"label":"Co-Ad Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged â‰¥50 YOA, as compared to the control group where the two HZ/su doses are administered subsequent to Prevenar13.","primaryOutcome":{"measure":"Percentage of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in Co-Ad Group","timeFrame":"One month post-dose 2 (Month 3)","effectByArm":[{"arm":"Co-Ad Group","deltaMin":99.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":13,"countries":["United States","Canada","Estonia","Germany"]},"refs":{"pmids":["34963639"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":449},"commonTop":["Injection site pain","Myalgia","Fatigue","Headache","Injection site erythema"]}}